Annexon, Inc (ANNX)

Etorro trading 970x250
Annexon, Inc (ANNX) Logo

About Annexon, Inc

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company’s candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington’s disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California. Address: 180 Kimball Way, South San Francisco, CA, United States, 94080

Annexon, Inc News and around…

Latest news about Annexon, Inc (ANNX) common stock and company :

We're Not Very Worried About Annexon's (NASDAQ:ANNX) Cash Burn Rate
19 Oct, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Peek Under The Hood: PBSM Has 20% Upside
05 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $46.22 per unit.

Annexon, Inc. (ANNX): Hedge Fund Sentiment Unchanged
04 Oct, 2021 Yahoo! Finance

While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious towards the current bull run since March, 2020 and hedging or reducing many of their long positions. Some fund managers are betting on Dow […]

Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer
04 Oct, 2021 Yahoo! Finance

– Dr. Ted Yednock’s appointment enhances Annexon’s commitment to scientific innovation and pursuit of future programs – – Dr. Larry Mattheakis brings decades of drug discovery and development expertise to support advancement of Annexon’s current and future pipeline – SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage company developing a new class of medicines for patients with classical complement-mediated autoimmune, neurod

52 Biggest Movers From Yesterday
30 Sep, 2021 FinancialContent

Gainers Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday. Smart Share Global Limited (NASDAQ: EM) ...

33 Stocks Moving In Wednesday's Mid-Day Session
29 Sep, 2021 FinancialContent

Gainers Paltalk, Inc. (NASDAQ: PALT) shares climbed 37% to $7.18. NuCana plc (NASDAQ: NCNA) jumped 31.4% to $3.1150. The FDA ...

Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
23 Sep, 2021 FinancialContent
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
20 Sep, 2021 FinancialContent
EVP And Chief Scientific Officer Of Annexon Trades $351.08 Thousand In Company Stock
16 Sep, 2021 Yahoo! Finance

Ted Yednock, EVP And Chief Scientific Officer at Annexon (NASDAQ:ANNX), made a large buy and sell of company shares on September 13, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission reports that on September 13, Ted Yednock bought 16,190 Annexon shares at prices ranging from $1.41 to $5.11 per share, for a total of $27,225. They then sold their shares on the same day in the open market at a price of $20.00 to raise a total of $323,860

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
20 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
16 Aug, 2021 FinancialContent
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
22 Jul, 2021 FinancialContent
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
22 Jul, 2021 Yahoo! Finance

Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis Deepening ANX005 neuromuscular autoimmune pipeline with new Phase 2 program in Multifocal Motor Neuropathy Annexon to host virtual autoimmune R&D event with leading experts on Wednesday, July 28, at 10:30 a.m. ET SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a class of next generation complement medicines

Annexon to Present at the Raymond James Human Health Innovation Conference
16 Jun, 2021 FinancialContent
Moving Average Crossover Alert: Annexon (ANNX)
21 May, 2021 Yahoo! Finance

Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
17 May, 2021 FinancialContent
Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference
05 May, 2021 FinancialContent
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
22 Apr, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights
25 Mar, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Intraday Session
17 Mar, 2021 FinancialContent

Gainers Lipocine (NASDAQ:LPCN) shares rose 21.42% to $1.87 during Wednesday's regular session. Lipocine's stock ...

Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
01 Mar, 2021 FinancialContent

Annexon Inc(NASDAQ:ANNX) hascommenced patient dosingin itsPhase 2 ARCHER studyevaluating ANX007 to ...

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy
01 Mar, 2021 FinancialContent
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
23 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

68 Biggest Movers From Yesterday
23 Feb, 2021 FinancialContent

Gainers ReTo Eco-Solutions, Inc. (NASDAQ: RETO) shares surged 98.3% to close at $2.34 on Monday. ReTo Eco-Solutions, last month, ...

12 Health Care Stocks Moving In Monday's Intraday Session
22 Feb, 2021 FinancialContent

Gainers Celsion (NASDAQ:CLSN) stock moved upwards by 60.78% to $3.06 during Monday's regular session. Trading volume ...

50 Stocks Moving In Monday's Mid-Day Session
22 Feb, 2021 FinancialContent

Gainers ReTo Eco-Solutions, Inc. (NASDAQ: RETO) shares jumped 112.3% to $2.5050. ReTo Eco-Solutions, last month, received ...

Annexon Welcomes William H. Carson, M.D. to the Board of Directors
08 Feb, 2021 FinancialContent

Thomas G. Wiggans appointed Chairman

Benzinga's Top Ratings Upgrades, Downgrades For January 26, 2021
26 Jan, 2021 FinancialContent

Upgrades For Beacon Roofing Supply Inc (NASDAQ:BECN), Longbow Research upgraded the previous rating of Neutral to Buy. ...

54 Biggest Movers From Friday
19 Jan, 2021 FinancialContent

Gainers Yield10 Bioscience, Inc. (NASDAQ: YTEN) shares jumped 76.9% to close at $13.71 on Friday. ObsEva SA (NASDAQ: OBSV) ...

Annexon, Inc (ANNX) is a NASDAQ Common Stock listed in , ,

970x250